Clinical trials

  • ISATUXIMAB for Acute lymphoblastic leukaemia | T-lymphoblastic lymphoma
  • Obinutuzumab for Marginal zone lymphoma | Nodal marginal zone B-cell lymphoma | Splenic marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma (MALT type)
  • exagamglogene autotemcel for Transfusion-dependent beta-thalassemia | Severe sickle cell disease
  • Filgotinib for Ulcerative colitis
  • BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis
  • PEMBROLIZUMAB for Metastatic renal cell carcinoma
  • Posaconazole for Allogeneic hematopoietic stem cell transplantation | Myeloid hematological malignancy | Lymphoid hematological malignancy | High risk of invasive fungal infection
  • DAZODALIBEP for Sjögren's syndrome
  • BIMEKIZUMAB for Plaque psoriasis | Psoriasis
  • Brentuximab vedotin for Peripheral T-cell lymphoma (PTCL) | Anaplastic large cell lymphoma (ALCL) | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Angioimmunoblastic T-cell lymphoma (AITL) | Adult T-cell leukaemia/lymphoma (ATLL) | Enteropathy-associated T-cell lymphoma (EATL) | Hepatosplenic T-cell lymphoma | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Follicular T-cell lymphoma | Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
  • ABO21009 for Rheumatoid arthritis
  • CISPLATIN for FIGO stage III high-grade serous ovarian cancer | Peritoneal cancer | Fallopian tube carcinoma